Invesco Ltd. Has $6.97 Million Stake in Janux Therapeutics, Inc. $JANX

Key Points

• Invesco Ltd. has reduced its stake in Janux Therapeutics, Inc. by 9.3%, now holding about 258,108 shares worth $6.97 million.
• Multiple institutional investors, including GAMMA Investing LLC and US Bancorp DE, significantly increased their stakes in Janux Therapeutics, with GAMMA boosting its position by 1,574%.
• Janux Therapeutics reported an EPS of ($0.55) for the last quarter, missing the consensus estimate by ($0.07), and is expected to post a yearly EPS of ($1.38).

Invesco Ltd. reduced its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 9.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 258,108 shares of the company's stock after selling 26,554 shares during the period. Invesco Ltd. owned about 0.44% of Janux Therapeutics worth $6,969,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in shares of Janux Therapeutics by 1,574.0% in the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock valued at $45,000 after acquiring an additional 1,574 shares during the last quarter. US Bancorp DE raised its position in Janux Therapeutics by 2,402.9% in the 1st quarter. US Bancorp DE now owns 1,727 shares of the company's stock valued at $47,000 after purchasing an additional 1,658 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Janux Therapeutics in the fourth quarter worth $59,000. FNY Investment Advisers LLC boosted its stake in Janux Therapeutics by 6,928.6% in the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock worth $66,000 after purchasing an additional 2,425 shares in the last quarter. Finally, KBC Group NV bought a new stake in shares of Janux Therapeutics during the first quarter worth $66,000. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Trading Down 1.4%

Janux Therapeutics stock traded down $0.33 during mid-day trading on Monday, hitting $22.72. The stock had a trading volume of 456,346 shares, compared to its average volume of 807,162. The stock has a 50-day simple moving average of $24.51 and a two-hundred day simple moving average of $26.99. The stock has a market capitalization of $1.37 billion, a PE ratio of -12.62 and a beta of 2.84. Janux Therapeutics, Inc. has a 12 month low of $21.97 and a 12 month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07). Sell-side analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Raymond James Financial assumed coverage on Janux Therapeutics in a report on Friday, July 11th. They issued an "outperform" rating and a $65.00 price target for the company. Piper Sandler started coverage on shares of Janux Therapeutics in a research report on Monday, August 18th. They issued an "overweight" rating and a $42.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $86.90.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.